


Supplementary Fig. S2 Downs and Black score of full-text observational studies (6 studies): oncology^{1,2} and chronic inflammatory disease³⁻⁶ studies.



References

1. Roy PS, et al. Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. *Indian J Med Paediatr Oncol.* 2013;34(4):292.
2. Thakral P, et al. An approach for conjugation of 177Lu-DOTA-SCN-rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients. *Indian J Med Res.* 2014;139(4):544.
3. Roshique KK, Ravindran V. Efficacy and safety of a biosimilar rituximab in biologic naive patients with active rheumatoid arthritis. *Clin Rheumatol.* 2015;34(7):1289-92.
4. Farkas K, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis—experiences from a single center. *Expert Opin Biol Ther.* 2015;15(9):1257-62.
5. Jung YS, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. *J Gastroenterol Hepatol.* 2015;30(12):1705-12.
6. Kang Y-S, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. *Dig Dis Sci.* 2015;60(4):951-6.